Obesity Management 2017

Click "Begin" to evaluate sessions, claim CME & Maintenance of Certification (MOC) points, and print a certificate of attendance or certificate of participation

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile
  2. Evaluate the MOC sessions you attended through this form

Review & Edit your Profile

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals treating overweight and obese individuals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Translational Insights into Sleep and Dysregulated Metabolism

  • Explain the relation of sleep disorders in the risk of obesity and potential treatment pathway
  • Evaluate patients for sleep apnea and discuss possible treatment strategies

Commercial Programs & Behavioral Prescriptions to Individualize Medical Interventions

  • Develop an approach to choosing a treatment strategy that is most optimal for managing obesity
  • Recognize the behavioral approaches to obesity management that are most impactful in practice
  • Explain the methods available for promoting lasting behavior change

Exercise Prescriptions to Individualize Medical Interventions

  • Explain the methods available for promoting lasting behavior change
  • Recognize the behavioral approaches to obesity management that are most impactful in practice
  • Discuss the usefulness of lifestyle and behavioral changes to reduce weight
  • Describe the most common issues in behavior change

Advocacy Interventions for Obesity: New Approaches to Evidence-Based Advocacy

  • Describe the effects of weight bias
  • Develop intervention strategies to reduce weight bias in the clinical setting

Obesity Management in Older Adults                  

  • Explain the role new agents have in assisting current therapeutic challenges
  • Manage OTC drugs with prescribed pharmacologic agents and their effect on weight loss efforts

Severe Obesity in Adolescents

  • Describe the best treatment strategies for overweight and obese youth

Post‐Operative Weight Regain and Pharmacotherapy

  • Define medically significant weight loss and its impact on glycemic parameters
  • Recognize the appropriate provocative test to evaluate hypoglycemia from bariatric surgery
  • Diagnose and manage dumping syndrome

Hormones Testing in the Evaluation of Weight Gain

  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight

Pharmacotherapy for Obesity Management

  • Describe the mechanism of action, safety, and efficacy of new medical therapies for obesity
  • Discuss the clinical data on pharmaceutical treatment options for obesity
  • Describe the weight consequences of certain pharmacologic therapies for obesity
  • Explore how approved and emerging weight‐ loss drugs may be appropriately integrated into a weight‐loss program
  • Manage OTC drugs with prescribed pharmacologic agents and their effect on weight loss efforts

Advances in Surgical Management

  • Explain the comparative effectiveness of the surgical treatments for obesity, including what is known about mechanisms of action

Use of Monitoring Devices to Track and Promote Adherence

  • Explain the differences between the various devices
  • Discuss the pros and cons of each device in the clinical setting

Managing the Patient with Obesity and Diabetes: Treat the Obesity First, or Treat the Diabetes First?

  • Select appropriate medical therapy options for the co‐management of diabetes and obesity
  • Explain the role new agents have in assisting current therapeutic challenges
  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 6.75 ABIM MOC
  • 6.75 AMA PRA Category 1 Credits
  • 6.75 CME Certificate of Participation
Course opens: 
Course expires: 
Event starts: 
03/31/2018 - 9:00am
Event ends: 
03/31/2018 - 5:00pm
Orange County Convention Center
Orlando, FL
United States

Program Chairs

Richard L. Atkinson, Jr., MD; Virginia Commonwealth Univ
Daniel H. Bessesen, MD, Univ of Colorado Sch of Med
Marc A. Cornier, MD; Univ of Colorado Sch of Med
William T. Donahoo, MD; Kaiser Permanente Colorado/Univ of Colorado Sch of Med


John A. Batsis, MD; Dartmouth‐Hitchcock Med Ctr
Stacy A. Brethauer, MD; Cleveland Clin
Francesco S. Celi, MD, MHSc; Virginia Commonwealth Univ
Timothy S. Church, MD, MPH, PhD; Pennington Biomed Res Ctr
Emily Dhurandhar, PhD; Texas Tech Univ​​​​​​​
William T. Donahoo, MD; Univ of Florida
Kenneth Fujioka, MD; Scripps Clin
Corby K. Martin, PhD; Pennington Biomed Res Ctr
Patrick M. O’Neil, PhD; Med Univ of South Carolina
Eve Van Cauter, PhD; Univ of Chicago
Susan J. Woolford, MD, MPH; Univ of Michigan


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

John A. Batsis, MD: Research Grant, Centers for Disease Control and Prevention Health Promotion Research Center, Dartmouth Centers for Health and Aging, Dartmouth Clinical and Translational Science Institute, National Institute on Aging, Norris Cotton Canter Center

Daniel Bessesen, MDData Safety Monitoring Board, EnteroMedics Inc.

Stacy A. Brethauer, MD: Speaker, Johnson & Johnson, Medtronic MiniMed, Inc.

Francesco S. Celi, MD, MHSc: Ad Hoc Consultant, Titan Pharmaceuticals, Inc.; Advisory Group Member, LioTriDev, LLC

William T. Donahoo, MD: Research Funds Distributed by the Univ of Florida Dept of Med, Gatorade Trust

Emily Dhurandhar, PhD: Consultant, Dhurandhar Weight Management, LLC

Kenneth Fujioka, MD: Investigator, Eisai Inc.; Scientific Board Member, KVK Tech, Inc.; Scientific Board Member and Speaker, Novo Nordisk Inc., Orexigen Therapeutics, Inc.

John L. Leahy, MD: Advisory Group Member, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC

Corby K. Martin, PhD: Consultant, ACAP Health; Academic work conducted via Pennington Biomed Res Ctr involving intellectual property co‐developed with colleagues, ABGIL

Patrick M. O’Neil, PhD: Advisory Board Member, Janssen Pharmaceuticals, Inc., Pfizer Inc.; Advisory Board Member and Honoraria, Novo Nordisk Inc.; Advisory Board Member and Research Funding, Orexigen Therapeutics, Inc.; Honoraria, Medscape/WebMD; Research Funding, Weight Watchers International

Eve Van Cauter, PhD: Advisory Group Member, Pfizer Inc.; Advisory Group Member, Principal Investigator, and Speaker, Novo Nordisk Inc.; Principal Investigator, Weight Watchers International

The following faculty reported no relevant financial relationships: Richard L. Atkinson, Jr., MD; Timothy S. Church, MD, MPH, PhD; Marc A. Cornier, MD; Susan J. Woolford, MD, MPH

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 6.75 ABIM MOC
  • 6.75 AMA PRA Category 1 Credits
  • 6.75 CME Certificate of Participation